The Seventh Beijing Forum on Evidence-Based Medicine and the 2026 eCMTA Journal Academic Symposium, held October 19–20 at Beijing University of Chinese Medicine (BUCM), brought together 28 experts from 14 countries and regions to address a central challenge: how to generate reliable evidence that can support the clinical value of traditional Chinese medicine (TCM) and integrate it into mainstream healthcare. The forum matters because it signals a sustained international push to subject TCM to the same standards of scientific scrutiny as conventional medicine, a shift that could reshape how traditional therapies are evaluated, regulated and adopted worldwide.
Co-hosted by BUCM’s Center for Evidence-Based Chinese Medicine and the Journal Center, the event coincided with BUCM’s 70th anniversary. Vice President Liu Cunzhi noted the university’s long-standing efforts to promote TCM–evidence-based medicine integration, while Journal Center Director Pan Yanshu emphasized that evidence-based medicine is “not tradition versus modernity but a way to test traditional medicine’s clinical value through modern science.” That framing is significant: it positions TCM not as an alternative to rigorous science but as a subject of it, potentially easing skepticism among regulators and clinicians in Western countries.
The participation of Gordon Guyatt, a founder of evidence-based medicine and professor at McMaster University, lent considerable weight to the proceedings. In his keynote, Guyatt stressed that evidence varies in reliability and that high-quality decisions require systematic appraisal while considering patients’ values and preferences. Nicola Robinson of London South Bank University challenged attendees with the question “What Counts as Evidence?”, arguing that trust demands rigorous research into real effects and risks—not individual success stories. These discussions are consequential because they set the methodological bar for TCM research, and meeting that bar is essential for international acceptance.
Practical challenges were also on the agenda. Lao Lixing of Virginia University of Integrative Medicine examined methodology in Chinese herbal medicine trials, Dennis Chang of Western Sydney University reviewed global trends in evidence-based integrative medicine, and Terje Alræk presented research on acupuncture for cancer-related fatigue in breast cancer patients. Such work demonstrates that TCM interventions can be studied with the same rigor as conventional treatments, producing evidence that clinicians can act on. Roundtables on TCM priority conditions and international cooperation, chaired by Fei Yutong and Cao Huijuan, further explored clinical advantages and research collaboration, while a young scholars’ session gave early-career researchers a platform to present work on clinical research, evidence evaluation and guideline development.
The eCMTA Journal Academic Symposium, held on October 20, underscored the role of publishing in this effort. Pan Yanshu affirmed the journal’s progress in internationalization and database indexing, and co-editor-in-chief Nicola Robinson reported on its development since launch. The journal is actively soliciting submissions through its manuscript submission portal and has waived article processing charges until December 31, 2027, a move that could attract high-quality research from resource-limited settings. More information about the journal is available at its SciOpen page.
Ultimately, the forum’s implications extend beyond academic exchange. By strengthening high-quality clinical research, promoting evidence translation and deepening international cooperation, the initiative aims to make TCM’s clinical value more scientifically understood—providing greater support for healthcare quality and public health. As global interest in integrative medicine grows, the outcomes of such collaborations will help determine whether TCM earns a trusted place in evidence-based practice.


